Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Biocon Biologics delivers 100 million insulin cartridges to Malaysia, commercializes biosimilars in key global markets with ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

Biotechnology firm Biocon Ltd announces its board's approval to acquire optionally convertible debentures of its subsidiary ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

Siddharth Mittal, CEO & MD of Biocon says the company will evaluate Biologics IPO after committee review; current focus is on ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

Biotechnology firm Biocon Ltd on Thursday said its board has approved the acquisition of optionally convertible debentures of ...

Supplies over 100 million cartridges of recombinant human insulin to Malaysia's Ministry of Health ...

Biocon Ltd acquires Biocon Biologics debentures from Goldman Sachs for USD 198.5 million. The acquisition involves 1,125 ...